Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019029541) FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/029541 International Application No.: PCT/CN2018/099242
Publication Date: 14.02.2019 International Filing Date: 07.08.2018
IPC:
C07D 487/04 (2006.01) ,C07D 475/00 (2006.01) ,C07D 471/04 (2006.01) ,A61K 31/519 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
475
Heterocyclic compounds containing pteridine ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
南京药捷安康生物科技有限公司 NANJING TRANSTHERA BIOSCIENCES CO. LTD. [CN/CN]; 中国江苏省南京市 高新区药谷大道11号加速器二期09栋3楼 3rd Floor, Building 9, Phase 2 Accelerator No. 11 Yaogu Avenue, High-Tech District Nanjing, Jiangsu 210032, CN
Inventors:
吴永谦 WU, Frank; CN
Agent:
北京柏杉松知识产权代理事务所(普通合伙) PATENTSINO IP FIRM; 中国北京市 西城区北三环中路27号商房大厦413室 Suite 413, Shang Fang Building No. 27 North Third Ring Road Middle, Xicheng District Beijing 100029, CN
Priority Data:
201710672089.X08.08.2017CN
Title (EN) FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF
(FR) INHIBITEUR DE RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES ET SON UTILISATION
(ZH) 成纤维细胞生长因子受体抑制剂及其用途
Abstract:
(EN) Provided are a fibroblast growth factor receptor (FGFR) irreversible inhibitor as represented by formula I, a pharmaceutically acceptable salt, a stereoisomer thereof, and pharmaceutical preparations, pharmaceutical compositions and uses of these compounds. Said compounds have an efficient and highly selective inhibitory effect on FGFR, and can be used for the treatment of related diseases mediated by FGF/FGFR abnormality, especially for the treatment of cancer diseases.
(FR) L'invention concerne un inhibiteur irréversible du récepteur du facteur de croissance des fibroblastes (FGFR) tel que représenté par la formule I, un sel pharmaceutiquement acceptable, un stéréoisomère de celui-ci, et des préparations pharmaceutiques, des compositions pharmaceutiques et des utilisations de ces composés. Lesdits composés ont un effet inhibiteur efficace et hautement sélectif sur FGFR, et peuvent être utilisés pour le traitement de maladies associées induites par une anomalie FGF/FGFR, en particulier pour le traitement de maladies cancéreuses.
(ZH) 提供式I所示的成纤维细胞成长因子受体(FGFR)不可逆抑制剂、其药学上可接受的盐、立体异构体,这些化合物的药物制剂、药物组合物及其应用。所述化合物对FGFR具有高效和高选择性的抑制作用,可用于FGF/FGFR异常介导的相关疾病治疗,尤其是用于癌症疾病方面的治疗。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)